This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.

Research Objectives

Status

Current

Recruitment

Open

Patient Group

Indication: Erythropoietic Protoporphyria(EPP)or X-Linked Protoporphyria(XLP)

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored

Sponsors: Mitsubishi Tanabe Pharma Development

Lead investigators

Prof David Coman

Clinical Trial Coordinator

Venita Bali

Technical title

A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

About this research project

Erythropoietic Protoporphyria (referred to as“EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.

Investigating treatments to reduce pain when skin is exposed to sunlight